

ADVENTRX PHARMACEUTICALS INC  
Form 8-K  
July 02, 2010

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

June 30, 2010

ADVENTRX Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-32157

84-1318182

(State or other jurisdiction  
of incorporation)

(Commission  
File Number)

(I.R.S. Employer  
Identification No.)

6725 Mesa Ridge Road, Suite 100, San Diego,  
California

92121

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code:

858-552-0866

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



**Top of the Form**

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

The annual meeting of stockholders of ADVENTRX Pharmaceuticals, Inc. (the Company) was held on June 30, 2010. The final voting results on each of the matters submitted to a vote of the Company's stockholders were as follows:

1. The stockholders elected each of the five nominees to the Company's board of directors, each to serve until the Company's 2011 annual meeting of stockholders and until their respective successors are elected and qualified, as follows:

| Nominee             | For       | Against | Abstain | Broker Non-Votes |
|---------------------|-----------|---------|---------|------------------|
| Michael M. Goldberg | 1,413,058 | 157,645 | 20,924  | 7,853,454        |
| Odysseas D. Kostas  | 1,411,768 | 159,953 | 19,907  | 7,853,453        |
| Jack Lief           | 1,409,903 | 161,308 | 20,416  | 7,853,454        |
| Mark J. Pykett      | 1,353,926 | 216,758 | 20,944  | 7,853,453        |
| Eric K. Rowinsky    | 1,411,289 | 161,177 | 19,161  | 7,853,454        |

2. The stockholders ratified the appointment of J.H. Cohn LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2010 as follows:

| For       | Against | Abstain |
|-----------|---------|---------|
| 8,945,881 | 410,635 | 88,565  |

---

**Top of the Form**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ADVENTRX Pharmaceuticals, Inc.

*July 2, 2010*

By: */s/ Patrick Keran*

---

*Name: Patrick Keran*

*Title: President and Chief Operating Officer*